MPN Voice

(4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for Treatment of Polycythemia Vera

(4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib  with Best Available Therapy for Treatment of Polycythemia Vera

pvreporter.com/dr-jean-jacq...

Hope you find the interview informative.

Best,

David - PV Reporter

oldestnewest

You may also like...